<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902888</url>
  </required_header>
  <id_info>
    <org_study_id>PAA 12-01</org_study_id>
    <nct_id>NCT01902888</nct_id>
  </id_info>
  <brief_title>Evaluation of GORE® VIABAHN® Endoprosthesis for Popliteal Artery Aneurysm</brief_title>
  <acronym>PAA 12-01</acronym>
  <official_title>Retrospective Evaluation of the GORE® VIABAHN® Endoprosthesis for a Popliteal Artery Aneurysm Indication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, non-randomized, single arm, retrospective study of GORE® VIABAHN®
      Endoprosthesis for the treatment of a Popliteal Artery Aneurysm (PAA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the safety and efficacy of the GORE® VIABAHN®
      Endoprosthesis for the treatment of subjects with Popliteal Artery Aneurysms. The study
      population includes subjects with an asymptomatic aneurysm (≥ 2 cm diameter) of the popliteal
      artery, symptomatic aneurysm (no diameter requirement) of the popliteal artery, or presence
      of mural thrombus (no diameter requirement) of the popliteal artery treated with the GORE®
      VIABAHN® Endoprosthesis between January 1, 2002 and December 31, 2010. Starting with most
      recently treated within the above date range, patients meeting Inclusion/Exclusion will be
      enrolled, until a minimum of 50 subjects with adequate follow up to determine primary
      endpoints through 12 months will be provided.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to internal and external factors.
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint: The Number of Patients That do Not Have a Failure of Technical Success or Loss of Primary Patency.</measure>
    <time_frame>12 months following initial study procedure</time_frame>
    <description>A composite of freedom from failure of technical success or loss of primary patency at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Number of Serious Adverse Events (Related to Initial Procedure or the Device Itself) That Occur Within 30 Days of the Initial Study Procedure.</measure>
    <time_frame>30 days following initial study procedure</time_frame>
    <description>30 day serious adverse events related to the initial study procedure or the study device.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3</enrollment>
  <condition>Popliteal Artery Aneurysm</condition>
  <arm_group>
    <arm_group_label>Popliteal aneurysm</arm_group_label>
    <description>GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® VIABAHN® Endoprosthesis</intervention_name>
    <arm_group_label>Popliteal aneurysm</arm_group_label>
    <other_name>Viabahn</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had popliteam aneurysm and were treated with GORE® VIABAHN® Endoprosthesis
        between January 1, 2002 and December 31, 2010.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received a GORE® VIABAHN® Endoprosthesis between January 1, 2002 and December 31, 2010
             to treat a popliteal artery aneurysm;

          -  Had an asymptomatic aneurysm (≥ 2 cm diameter) of the popliteal artery, or symptomatic
             aneurysm (no diameter requirement) of the popliteal artery, or the presence of mural
             thrombus (no diameter requirement) of the popliteal artery;

          -  Was 18 years of age or older; and

          -  Had an elective popliteal artery aneurysm procedure.

        Exclusion Criteria:

          -  Bilateral popliteal artery aneurysms with initial treatment on the same day

          -  Had previous surgery for the popliteal artery aneurysm in the study limb
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector Novoa, BS</last_name>
    <role>Study Director</role>
    <affiliation>W. L. Gore &amp; Associates, Inc (sponsor)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vascular Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <results_first_submitted>May 19, 2015</results_first_submitted>
  <results_first_submitted_qc>June 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2015</results_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>popliteal artery</keyword>
  <keyword>aneurysm</keyword>
  <keyword>popliteal artery aneurysm</keyword>
  <keyword>asymptomatic aneurysm</keyword>
  <keyword>mural thrombus</keyword>
  <keyword>Viabahn</keyword>
  <keyword>Gore</keyword>
  <keyword>Endoprosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Popliteal Aneurysm</title>
          <description>GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
GORE® VIABAHN® Endoprosthesis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Popliteal Aneurysm</title>
          <description>GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
GORE® VIABAHN® Endoprosthesis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Endpoint: The Number of Patients That do Not Have a Failure of Technical Success or Loss of Primary Patency.</title>
        <description>A composite of freedom from failure of technical success or loss of primary patency at 12 months</description>
        <time_frame>12 months following initial study procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Popliteal Aneurysm</title>
            <description>GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
GORE® VIABAHN® Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Endpoint: The Number of Patients That do Not Have a Failure of Technical Success or Loss of Primary Patency.</title>
          <description>A composite of freedom from failure of technical success or loss of primary patency at 12 months</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint: Number of Serious Adverse Events (Related to Initial Procedure or the Device Itself) That Occur Within 30 Days of the Initial Study Procedure.</title>
        <description>30 day serious adverse events related to the initial study procedure or the study device.</description>
        <time_frame>30 days following initial study procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Popliteal Aneurysm</title>
            <description>GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
GORE® VIABAHN® Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint: Number of Serious Adverse Events (Related to Initial Procedure or the Device Itself) That Occur Within 30 Days of the Initial Study Procedure.</title>
          <description>30 day serious adverse events related to the initial study procedure or the study device.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Popliteal Aneurysm</title>
          <description>GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
GORE® VIABAHN® Endoprosthesis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of study. No subject analysis done</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Arthur Scott / Clinical Study Manager</name_or_title>
      <organization>W.L. Gore and Associates, Inc.</organization>
      <phone>623.208.3365</phone>
      <email>artscott@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

